# US 2006/0153853 A1 · Altered insulin-like grwoth factor binding proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153853 A1
- Document ID: US20060153853A1
- Status: Published application
- Kind: A1
- Application number: 10/519,890
- Filed: 2003-07-11
- Published: 2006-07-13
- Earliest claimed: 2002-07-12
- Assignees: The University of Adelaide
- Inventors: Briony Forbes
- Web page: https://patentgrep.com/patent/US20060153853A1

## CPC

- C07H 21/04: with deoxyribosyl as saccharide radical
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 13/08: of the prostate
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 14/4743: {Insulin-like growth factor binding protein}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Altered IGFBPs are able to bind IGF, but the release is inhibited by resistance to protease cleavage and/or reduced binding to extracellular matrix (ECM). Alterations have been made in IGFBP-2 to the linker domain in particular and to two amino acid motifs found to be important for ECM binding. IGF-1 mediated proliferation of cancer cells have been inhibited by use of the altered IGFBPs.

## Claims

### Claim 1

An altered IGFBP-2 molecule able to effect binding of IGF-I or IGF-II with high affinity wherein an inhibited release of IGF occurs on contact with an extracellular matrix or exposure to a protease.

### Claim 2 (depends on 1)

An altered IGFBP molecule of claim 1 wherein the IGFBP-2 molecule has an alteration in one or more amino acids of a first ECM binding sequence which spans amino acids 179-184 and comprises the sequence PKKLRP.

### Claim 3 (depends on 1)

An altered IGFBP molecule as in claim 1 wherein the altered IGFBP-2 molecule has an alteration in one or more amino acids of a second ECM binding sequence which spans amino acids 227-244 and comprises the sequence KHGLYNLKQCKMSLNGQR.

### Claim 4 (depends on 2)

An altered IGFBP molecule as in claim 2 wherein the alteration in the first ECM binding sequence is selected from the group consisting of SEQ ID No 9, SEQ ID No 10, SEQ ID No 11, SEQ ID No 12 and SEQ ID No 13.

### Claim 5 (depends on 3)

An altered IGFBP molecule as in claim 3 wherein the alteration in the second ECM binding sequence is selected from the group consisting of SEQ ID No 14, SEQ ID No 15, SEQ ID No 16, SEQ ID No 17 and SEQ ID No 18.

### Claim 6 (depends on 1)

An altered IGFBP molecule as in claim 1 wherein the amino acid sequence is altered as one or both of K180A and K181A.

### Claim 7 (depends on 2)

An altered IGFBP molecule as in claim 2 wherein the IGFBP-2 molecule has additionally an alteration of its amino acid sequence that enhances resistance to proteolysis by one or more proteases.

### Claim 8 (depends on 7)

An altered IGFBP molecule as in claim 7 wherein the IGFBP-2 molecule has an amino acid sequence altered in the linker domain to provide resistance to said one or more proteases.

### Claim 9 (depends on 7)

An altered IGFBP molecule as in claim 7 having one or more amino acids deleted within the linker domain.

### Claim 10 (depends on 7)

An altered IGFBP molecule as in claim 7 wherein substantially all of the linker domain is deleted, but said altered molecule still retains amino acids from about 180 through to 191.

### Claim 11 (depends on 7)

An altered IGFBP molecule as in claim 7 wherein the IGFBP-2 molecule has a deletion of amino acids 114 through to 170.

### Claim 12 (depends on 1)

An altered IGFBP molecule as in claim 1 wherein the IGFBP-2 molecule additionally has an amino acid sequence altered to enhances resistance to proteolysis by one or more proteases.

### Claim 13 (depends on 1)

An altered IGFBP molecule as in claim 1 wherein the IGFBP-2 molecule has an amino acid sequence alteration in the linker domain to provide resistance to said one or more proteases.

### Claim 14 (depends on 1)

An altered IGFBP molecule as in claim 1 having one or more amino acids deleted within the linker domain.

### Claim 15 (depends on 1)

An altered IGFBP molecule as in claim 1 wherein substantially all of the linker domain is deleted, but said altered molecule still retains amino acids from about 180 through to 191.

### Claim 16 (depends on 1)

An altered IGFBP molecule as in claim 1 wherein the IGFBP-2 molecule has a deletion of amino acids 114 through to 170.

### Claim 17 (depends on 13)

An altered IGFBP molecule as in claim 13 wherein the amino acid sequence is altered at one or both positions as follows K180A and K181A.

### Claim 18

A nucleic acid encoding an altered IGFBP-2 molecule, said altered IGFBP molecule able to effect binding of IGF-I or IGF-II with high affinity wherein an inhibited release of IGF occurs on contact with an extracellular matrix or exposure to a protease.

### Claim 19 (depends on 18)

A nucleic acid encoding an altered IGFBP molecule as in claim 18 wherein the IGFBP-2 molecule has an alteration in one or more amino acids of a first ECM binding sequence which spans amino acids 179-184 and comprises the sequence PKKLRP.

### Claim 20 (depends on 18)

A nucleic acid encoding an altered IGFBP molecule as in claim 18 wherein the altered IGFBP-2 molecule has an alteration in one or more amino acids of a second ECM binding sequence which spans amino acids 227-244 and comprises the sequence KHGLYNLKQCKMSLNGQR.

### Claim 21 (depends on 19)

A nucleic acid encoding an altered IGFBP molecule as in claim 19 wherein the alteration in the first ECM binding sequence is selected from the group consisting of SEQ ID No 9, SEQ ID No 10, SEQ ID No 11, SEQ ID No 12 and SEQ ID No 13.

### Claim 22 (depends on 20)

A nucleic acid encoding an altered IGFBP molecule as in claim 20 wherein the alteration in the second ECM binding sequence is selected from the group consisting of SEQ ID No 14, SEQ ID No 15, SEQ ID No 16, SEQ ID No 17 and SEQ ID No 18.

### Claim 23 (depends on 18)

A nucleic acid encoding an altered IGFBP molecule as in claim 18 wherein the amino acid sequence is altered in one or both of K180A and K181A.

### Claim 24 (depends on 19)

A nucleic acid encoding an altered IGFBP molecule as in claim 19 wherein the IGFBP-2 molecule has additionally an alteration of its amino acid sequence that enhances resistance to proteolysis by one or more proteases.

### Claim 25 (depends on 24)

A nucleic acid encoding an altered IGFBP molecule as in claim 24 wherein the IGFBP-2 molecule has an amino acid sequence alteration in the linker domain to provide resistance to said one or more proteases.

### Claim 26 (depends on 24)

A nucleic acid encoding an altered IGFBP molecule as in claim 24 having one or more amino acids deleted within the linker domain.

### Claim 27 (depends on 24)

A nucleic acid encoding an altered IGFBP molecule as in claim 24 wherein substantially all of the linker domain is deleted, but said altered molecule still retains amino acids from about 180 through to 191.

### Claim 28 (depends on 24)

A nucleic acid encoding an altered IGFBP molecule as in claim 24 wherein the IGFBP-2 molecule has a deletion of amino acids 114 through to 170.

### Claim 29 (depends on 24)

A nucleic acid encoding an altered IGFBP molecule as in claim 24 wherein the IGFBP-2 molecule additionally has an amino acid sequence altered to enhance resistance to proteolysis by one or more proteases.

### Claim 30 (depends on 18)

A nucleic acid encoding an altered IGFBP molecule as in claim 18 wherein the IGFBP-2 molecule has an amino acid sequence altered in the linker domain to provide resistance to said one or more proteases.

### Claim 31 (depends on 18)

A nucleic acid encoding an altered IGFBP molecule as in claim 18 having one or more amino acids deleted within the linker domain.

### Claim 32 (depends on 18)

A nucleic acid encoding an altered IGFBP molecule as in claim 18 wherein substantially all of the linker domain is deleted, but said altered molecule still retains amino acids from about 180 through to 191.

### Claim 33 (depends on 18)

A nucleic acid encoding an altered IGFBP molecule as in claim 18 wherein the IGFBP-2 molecule has a deletion of amino acids 114 through to 170.

### Claim 34 (depends on 29)

A nucleic acid encoding an altered IGFBP molecule as in claim 29 wherein the amino acid sequence is altered at one or both positions as follows K180A and K181A.

### Claim 35 (depends on 18)

A nucleic acid encoding an altered IGFBP molecule as in claim 18 wherein the nucleic acid is a vector, the vector having nucleic acid operably linked with a control sequence including a promoter for transcription leading to expression of the altered IGFBP.

### Claim 36 (depends on 18)

A host cell carrying a nucleic acid as in claim 18.

### Claim 37 (depends on 1)

A method of reducing IGF mediated proliferation of a population of cancerous cells, the method including the step of contacting the population of cells with an altered IGFBP as in claim 1.

### Claim 38 (depends on 37)

The method of reducing IGF mediated proliferation of a population of cancerous cells as in claim 37 wherein the cancerous cells are selected from the group consisting of prostate, colon and breast cancer cells.

### Claim 39 (depends on 37)

The method of reducing IGF mediated proliferation of a population of cancerous cells as in claim 37 wherein the cancerous cells are colon cancer cells.

### Claim 40 (depends on 3)

An altered IGFBP molecule as in claim 3 wherein the IGFBP-2 molecule has additionally an alteration of its amino acid sequence that enhances resistance to proteolysis by one or more proteases.

### Claim 41 (depends on 20)

A nucleic acid encoding an altered IGFBP molecule as in claim 20 wherein the IGFBP-2 molecule has additionally an alteration of its amino acid sequence that enhances resistance to proteolysis by one or more proteases.
